Topical Diclofenac 2% (Pennsaid) for Knee OA Pain Clears FDA

Megan Brooks

January 17, 2014

The US Food and Drug Administration (FDA) has approved diclofenac sodium topical solution 2% w/w (Pennsaid 2%) for knee pain caused by osteoarthritis (OA), Nuvo Research Inc announced today.

Pennsaid 2% is a follow-on product to original Pennsaid 1.5% w/w, which has been available in the United States since 2010, the company notes in a statement.

Pennsaid 2% is supplied in a metered dose pump bottle and has been approved for twice-daily dosing compared with 4 times a day for original Pennsaid 1.5%.

Pennsaid 2% will be the first twice-daily dosed topical nonsteroidal anti-inflammatory drug (NSAID) available in the United States for the treatment of knee OA pain, the company said.

Pennsaid is contraindicated in patients with a known hypersensitivity to diclofenac sodium or any other component of Pennsaid and in patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. Severe, rarely fatal, anaphylactic-like reactions to NSAIDs have been reported in such patients.

Nuvo has licensed the US sales and marketing rights for both Pennsaid 1.5% and Pennsaid 2% to Mallinckrodt. Mallinckrodt plans to launch Pennsaid 2% in the United States in the first quarter of 2014.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.